From April 25 to April 30, 2025, U.S. time, ImmVira presented the Phase I clinical results of its oncolytic Herpes Simplex Virus ("oHSV") product MVR-C5252 targeting malignant glioma through poster ...

During a major phase III trial, pembrolizumab combined with standard treatment kept cancer at bay for an average of 60 months ...

Abpro Holdings (ABP) and Celltrion unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the American Association for Cancer ...

Report Ocean has published a new report on the Saudi Arabia Immuno-oncology Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report ...

Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profileAbpro and Celltrion have a strategic partnership for worldwide development and commercialization of ...

BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events ...

PASADENA, CA, USA I April 26, 2025 I GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform that ...